Cardiovascular effects of nebivolol in spontaneously hypertensive rats persist after treatment withdrawal

Abstract

The nebivolol antihypertensive effect was accompanied by an important reduction of hypertrophy and collagen deposition in both vascular and left ventricle tissue, which was maintained after a long period of therapy withdrawal.

A novel hydrodynamic approach of drag-reducing polymers to improve left ventricular hypertrophy and aortic remodeling in spontaneously hypertensive rats

“…DRP solution was prepared by polyethylene oxide (PEO; Sigma-Aldrich Co., St Louis, MO, USA), with an average molecular weight (MW) of 5×10 6 Da. The polymer was carefully dissolved in normal saline (NS) at a concentration of 1,000 ppm, avoiding mechanical shear degradation of the long-chain macromolecules, and then dialyzed against NS for 24 hours using a membrane (Regenerated Cellulose dialysis membrane, Spectra; Spectrum Laboratories Inc., NJ, USA) with 50-kDa MW cutoff.…”

“…[1][2][3][4] Cardiac remodeling is defined as genome expression resulting in molecular, cellular and interstitial changes and manifested clinically as myocardial hypertrophy, fibrosis and cardiac decompensation. 1,5 Aortic remodeling is characterized by impaired endothelium-dependent vasodilation and structural vascular changes; 6 thus, endothelium plays a primary role in the modulation of vascular tone and structure.…”

Effect of nebivolol on beat-to-beat and short-term blood pressure variability in spontaneously hypertensive rats

“…Although in vivo pharmacodynamic properties of nebivolol have been previously investigated in SHR (Mason et al 2006;Guerrero et al 2006;Guerrero et al 2003;van de Water et al 1988), these studies show some limitations, including the lack of comparison with normotensive control animals and the absence of the study of pharmacokinetic parameters. In addition, to the best our knowledge, nebivolol effects on blood pressure variability have not been studied in SHR and human subjects.…”

Kinetics of cardiac and vascular remodeling by spontaneously hypertensive rats after discontinuation of long-term captopril treatment

“…Some studies have shown that the long-term use of captopril in SHR in the prehypertensive phase is able not only to prevent the development of high blood pressure levels and cardiac hypertrophy, but also to maintain low blood pressure levels even after discontinuation of its use (2,12). These findings differ from those obtained with other antihypertensive drugs administered to SHR such as β-blockers, vasodilators and calcium antagonists, whose discontinuation results in a return of blood pressure levels www.bjournal.com.br Braz J Med Biol Res 43(4) 2010 equivalent to those seen in untreated animals (13,14). Freslon and Giudicelli (12), for example, observed that treatment with captopril and hydralazine normalized blood pressure.…”